Stock VINC VINCERX PHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Vincerx Pharma, Inc.

Equities

VINC

US92731L1061

Real-time Estimate Cboe BZX
Other stock markets
 02:10:58 2024-06-10 pm EDT 		5-day change 1st Jan Change
0.72 USD +1.12% Intraday chart for Vincerx Pharma, Inc. +15.37% -38.17%
Apr. 26 Tech Rally Boosts Exchange-Traded Funds, Equity Futures Pre-Bell Friday MT
Apr. 26 Vincerx Pharma Prices Public Offering of Shares, Warrants MT

Evolution of the average Target Price on Vincerx Pharma, Inc.

Price target over the last 5 years

History of analyst recommendation changes

1585d3a0613a71f15923ca37d30b.m5Tm4I4_rTrdUn8_yqcbx8eMk2Wzb8vrUT6ilY7ldYg.-sTU1KMI3kyXMRR9qfRJ8-q6xgbpB4azEw7X3-WuAr7C-o2x6mveVI9iPg~3e27cd72bf5603becd55c64ddee993ee

Analyst Recommendations on Vincerx Pharma, Inc.

Chardan Trims Price Target on Vincerx Pharma to $3 From $4, Keeps Buy Rating MT
SVB Securities Adjusts Vincerx Pharma's Price Target to $5 From $6, Keeps Outperform Rating MT
Cantor Fitzgerald Adjusts Vincerx Pharma's Price Target to $8 From $22, Reiterates Overweight Rating MT
Chardan Cuts Price Target on Vincerx Pharma to $4 From $11 as it Shifts VIP152 Launch to 2026 From 2024 Reiterates Buy Rating MT
SVB Securities Adjusts Vincerx Pharma's Price Target to $6 From $19, Keeps Outperform Rating MT
B. Riley Adjusts Vincerx Pharma Price Target to $6 From $12, Maintains Buy Rating MT
Chardan Cuts Price Target on Vincerx Pharma to $4 From $11 on Adjusted VIP152 Estimates, Reiterates Buy Rating MT
Chardan Lowers Vincerx Pharma's Price Target to $11 From $14, Buy Rating Kept MT
B. Riley Lowers Vincerx Pharma's Price Target to $12 from $26, Says May Need to Raise Additional Capital Under Unfavorable Conditions; Keeps Buy Rating MT
SVB Leerink Adjusts Vincerx Pharma's Price Target to $20 from $24, Keeps Outperform Rating MT
HC Wainwright Adjusts Vincerx Pharma's Price Target to $28 From $25, Reiterates Buy Rating MT
HC Wainwright Starts Vincerx Pharma at Buy With $25 Price Target MT
Cantor Fitzgerald Starts Vincerx Pharma at Overweight With $25 Price Target MT
SVB Leerink Starts Vincerx Pharma at Outperform with $24 Price Target MT
VINCERX PHARMA : Laidlaw & Co. Starts Vincerx Pharma at Buy with $30 Price Target MT
VINCERX PHARMA : B. Riley Starts Vincerx Pharma at Buy with $26 PT, Says Shares Offer 'Attractive' Entry Point Ahead of VIP152 Clinical Updates; Keeps Buy Rating MT
VINCERX PHARMA : Chardan Adjusts Price Target on Vincerx to $30 From $33, Citing 'Forward OpEx Estimates, Recent Dilution;' Buy Rating Kept MT
VINCERX PHARMA : Chardan Starts Vincera Pharma at Buy With $33 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.712 USD
Average target price
7 USD
Spread / Average Target
+883.15%
High Price Target
10 USD
Spread / Highest target
+1,304.49%
Low Price Target
4 USD
Spread / Lowest Target
+461.80%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Vincerx Pharma, Inc.

Chardan Research
SVB Securities LLC
Cantor Fitzgerald
B. Riley
HC Wainwright
SVB Leerink
Laidlaw & Co.
Chardan

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. VINC Stock
  4. Consensus Vincerx Pharma, Inc.